(
out of
64
reviews
)
Clinical Locations
Primary Location
Huntsman Cancer Institute - Cancer Hospital South
Radiation Oncology
1950 Circle of Hope
Salt Lake City
,
UT
84112
Patient Rating
4.9
/5
( out of
64 reviews
)
The patient rating score is an average of all responses on our patient experience survey. The rating averages scores for all questions about care from our providers. The scale on which responses are measured is 1 to 5 with 5 being the best score.
Patient comments are gathered from our patient experience survey and displayed in their entirety. For the convenience of our visitors, some patient comments have been translated from their original language into English while preserving their original meaning as accurately as possible. Patients are de-identified for confidentiality and patient privacy.
Board Certification and Academic Information
| Academic Departments |
Radiation Oncology
-Professor |
|---|
Education history
| Undergraduate | Biology - UCLA | B.S. |
|---|---|---|
| Doctoral Training | Biochemistry - Tufts University | Ph.D. |
| Professional Medical | Medicine - Tufts University School of Medicine | M.D. |
| Internship | Internal Medicine - University of Utah School of Medicine | Intern |
| Residency | Radiation Oncology - University of Utah School of Medicine | Resident |
| Chief Resident | Radiation Oncology - University of Utah School of Medicine | Chief Resident |
Selected Publications
Journal Article
- Lee H, Shen J, Fadlullah MZ, Neibling A, Hanson C, Ampaw E, Lin T, Larsen M, Lloyd J, Maughan BL, Swami U, Gupta S, Tward J, Johnson SB, O'Neil B, Schmidt B, Dechet CB, Haaland B, Wang L, Tan AC, Kohli (2025). Circulatory prostate cancer proteome landscapes and prognostic biomarkers in metastatic castrate resistant prostate cancer. Clinical proteomics, 22(1), 13.
- Galarza Fortuna GM, Grass D, Maughan BL, Jain RK, Dechet C, Beck J, Schuetz E, Sanchez A, O'Neil B, Poch M, Li R, Lloyd S, Tward J, Phunrab T, Hawks JL, Swami U, Boucher KM, Agarwal N, Gupta (2025). Nivolumab adjuvant to chemo-radiation in localized muscle-invasive urothelial cancer: primary analysis of a multicenter, single-arm, phase II, investigator-initiated trial (NEXT). Journal for immunotherapy of cancer, 13(3),
- Tward J, Lloyd S, Johnson S, Dechet C, Nei BO, Maughan B, Swami U, Gupta S, Sanchez A, Kokeny K, Agarwal (2025). A Phase 2 Trial of Radium(223) and Stereotactic Ablative Radiation Therapy in Hormone-Naïve Men with Oligometastatic Prostate Cancer to Bone: The RadSABR Study. International journal of radiation oncology, biology, physics,
- Li X, Bhagroo S, Su FC, Rahimi R, Tward (2025). Enhancing inguinal tumor treatment outcomes with a customized 3D-printed bolus. Journal of applied clinical medical physics, 26(7), e70175.
- Hutten RJ, Odei B, Johnson SB, Tward J (2024). Validation of the Combined Clinical Cell-Cycle Risk Score to Prognosticate Early Prostate Cancer Metastasis From Biopsy Specimens and Comparison With Other Routinely Used Risk Classifiers. JCO precision oncology, 8, e2300364.
- Sung D, Schmidt B, Tward J (2024). The Ability of the STAR-CAP Staging System to Prognosticate the Risk of Subsequent Therapies and Metastases After Initial Treatment of M0 Prostate Cancer. Clinical genitourinary cancer,
- Tward JD, Lenz L, Gutin A, Clegg W, Kasten CR, Finch R, Cohen T, Michalski J, Kishan A (2024). Using the Cell-Cycle Risk Score to Predict the Benefit of Androgen-Deprivation Therapy Added to Radiation Therapy in Patients With Newly Diagnosed Prostate Cancer. JCO precision oncology, 8, e2300722.
- Aßmann ES, Ose J, Hathaway CA, Oswald LB, Hardikar S, Himbert C, Chellam V, Lin T, Daniels B, Kirchhoff AC, Gigic B, Grossman D, Tward J, Varghese TK Jr, Shibata D, Figueiredo JC, Toriola AT, Beck A, Scaife C, Barnes CA, Matsen C, Ma DS, Colman H, Hunt JP, Jones KB, Lee CJ, Larson M, Onega T, Akerley WL, Li CI, Grady WM, Schneider M, Dinkel A, Islam JY, Gonzalez BD, Otto AK, Penedo FJ, Siegel EM, Tworoger SS, Ulrich CM, Peoples A (2024). Risk factors and health behaviors associated with loneliness among cancer survivors during the COVID-19 pandemic. Journal of behavioral medicine, 47(3), 405-421.
- Flaig TW, Spiess PE, Abern M, Agarwal N, Bangs R, Buyyounouski MK, Chan K, Chang SS, Chang P, Friedlander T, Greenberg RE, Guru KA, Herr HW, Hoffman-Censits J, Kaimakliotis H, Kishan AU, Kundu S, Lele SM, Mamtani R, Mian OY, Michalski J, Montgomery JS, Parikh M, Patterson A, Peyton C, Plimack ER, Preston MA, Richards K, Sexton WJ, Siefker-Radtke AO, Stewart T, Sundi D, Tollefson M, Tward J, Wright JL, Cassara CJ, Gurski L (2024). NCCN Guidelines® Insights: Bladder Cancer, Version 3.2024. Journal of the National Comprehensive Cancer Network, 22(4), 216-225.
- Roach E, Hutten R, Johnson S, Suneja G, Tward J, Petereit D, Gaffney (2024). The impact of a positive COVID-19 test on timeliness of radiation in patients receiving brachytherapy. Brachytherapy, 23(3), 360-367.
- Schaeffer EM, Srinivas S, Adra N, An Y, Bitting R, Chapin B, Cheng HH, D'Amico AV, Desai N, Dorff T, Eastham JA, Farrington TA, Gao X, Gupta S, Guzzo T, Ippolito JE, Karnes RJ, Kuettel MR, Lang JM, Lotan T, McKay RR, Morgan T, Pow-Sang JM, Reiter R, Roach M, Robin T, Rosenfeld S, Shabsigh A, Spratt D, Szmulewitz R, Teply BA, Tward J, Valicenti R, Wong JK, Snedeker J, Freedman-Cass D (2024). NCCN Guidelines® Insights: Prostate Cancer, Version 3.2024. Journal of the National Comprehensive Cancer Network, 22(3), 140-150.
- Tward JD, Huang HC, Esteva A, Mohamad O, van der Wal D, Simko JP, DeVries S, Zhang J, Joun S, Showalter TN, Schaeffer EM, Morgan TM, Monson JM, Wallace JA, Bahary JP, Sandler HM, Spratt DE, Rodgers JP, Feng FY, Tran P (2024). Prostate Cancer Risk Stratification in NRG Oncology Phase III Randomized Trials Using Multimodal Deep Learning With Digital Histopathology. JCO precision oncology, 8, e2400145.
- Patel SA, Ma TM, Wong JK, Stish BJ, Dess RT, Pilar A, Reddy C, Wedde TB, Lilleby WA, Fiano R, Merrick GS, Stock RG, Demanes DJ, Moran BJ, Tran PT, Krauss DJ, Abu-Isa EI, Pisansky TM, Choo CR, Song DY, Greco S, Deville C, DeWeese TL, Tilki D, Ciezki JP, Karnes RJ, Nickols NG, Rettig MB, Feng FY, Berlin A, Tward JD, Davis BJ, Reiter RE, Boutros PC, Romero T, Horwitz EM, Tendulkar RD, Steinberg ML, Spratt DE, Xiang M, Kishan A (2023). External Beam Radiation Therapy With or Without Brachytherapy Boost in Men With Very-High-Risk Prostate Cancer: A Large Multicenter International Consortium Analysis. International journal of radiation oncology, biology, physics, 115(3), 645-653.
- Parsons MW, Rock C, Chipman JJ, Shah HR, Hu B, Stephens DM, Tao R, Tward JD, Gaffney D (2023). Secondary malignancies in non-Hodgkin lymphoma survivors: 40¿years of follow-up assessed by treatment modality. Cancer medicine, 12(3), 2624-2636.
- Spratt DE, Tang S, Sun Y, Huang HC, Chen E, Mohamad O, Armstrong AJ, Tward JD, Nguyen PL, Lang JM, Zhang J, Mitani A, Simko JP, DeVries S, van der Wal D, Pinckaers H, Monson JM, Campbell HA, Wallace J, Ferguson MJ, Bahary JP, Schaeffer EM, Consortium NPCA, Sandler HM, Tran PT, Rodgers JP, Esteva A, Yamashita R, Feng F (2023). Artificial Intelligence Predictive Model for Hormone Therapy Use in Prostate Cancer.
- Fenlon JB, Nelson G, Teague KM, Coleman S, Shrieve D, Tward (2023). A Dosimetric Correlation Between Radiation Dose to Bone and Reduction of Hemoglobin Levels After Radiotherapy for Prostate Cancer. International journal of radiation oncology, biology, physics, 118(1), 85-93.
- Hutten RJ, Weil CR, King AJ, Barney B, Bylund CL, Fagerlin A, Gaffney DK, Gill D, Scherer L, Suneja G, Tward JD, Warner EL, Werner TL, Whipple G, Evans J, Johnson S (2023). Multi-Institutional Analysis of Cancer Patient Exposure, Perceptions, and Trust in Information Sources Regarding Complementary and Alternative Medicine. JCO oncology practice, 19(11), OP2300179.
- Spratt DE, Tang S, Sun Y, Huang HC, Chen E, Mohamad O, Armstrong AJ, Tward JD, Nguyen PL, Lang JM, Zhang J, Mitani A, Simko JP, DeVries S, van der Wal D, Pinckaers H, Monson JM, Campbell HA, Wallace J, Ferguson MJ, Bahary JP, Schaeffer EM, Sandler HM, Tran PT, Rodgers JP, Esteva A, Yamashita R, Feng F (2023). Artificial Intelligence Predictive Model for Hormone Therapy Use in Prostate Cancer. NEJM evidence, 2(8), EVIDoa2300023.
- Schaeffer EM, Srinivas S, Adra N, An Y, Barocas D, Bitting R, Bryce A, Chapin B, Cheng HH, D'Amico AV, Desai N, Dorff T, Eastham JA, Farrington TA, Gao X, Gupta S, Guzzo T, Ippolito JE, Kuettel MR, Lang JM, Lotan T, McKay RR, Morgan T, Netto G, Pow-Sang JM, Reiter R, Roach M, Robin T, Rosenfeld S, Shabsigh A, Spratt D, Teply BA, Tward J, Valicenti R, Wong JK, Shead DA, Snedeker J, Freedman-Cass D (2023). Prostate Cancer, Version 4.2023, NCCN Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network, 21(10), 1067-1096.
- Sung D, Sanchez A, Tward J (2023). Successful Salvage Brachytherapy after Infusion of Gold AuroShell Nanoshells for Localized Prostate Cancer in a Human Patient. Advances in radiation oncology, 8(4), 101202.
- Wang KM, Rickards AJ, Bingham T, Tward JD, Price R (2022). Technical note: Evaluation of a silicone-based custom bolus for radiation therapy of a superficial pelvic tumor. Journal of applied clinical medical physics, 23(4), e13538.
- Kishan AU, Steigler A, Denham JW, Zapatero A, Guerrero A, Joseph D, Maldonado X, Wong JK, Stish BJ, Dess RT, Pilar A, Reddy C, Wedde TB, Lilleby WA, Fiano R, Merrick GS, Stock RG, Demanes DJ, Moran BJ, Tran PT, Martin S, Martinez-Monge R, Krauss DJ, Abu-Isa EI, Pisansky TM, Choo CR, Song DY, Greco S, Deville C, McNutt T, DeWeese TL, Ross AE, Ciezki JP, Tilki D, Karnes RJ, Tosoian JJ, Nickols NG, Bhat P, Shabsovich D, Juarez JE, Jiang T, Ma TM, Xiang M, Philipson R, Chang A, Kupelian PA, Rettig MB, Feng FY, Berlin A, Tward JD, Davis BJ, Reiter RE, Steinberg ML, Elashoff D, Boutros PC, Horwitz EM, Tendulkar RD, Spratt DE, Romero (2022). Interplay Between Duration of Androgen Deprivation Therapy and External Beam Radiotherapy With or Without a Brachytherapy Boost for Optimal Treatment of High-risk Prostate Cancer: A Patient-Level Data Analysis of 3 Cohorts. JAMA oncology, 8, e216871.
- Hutten R, Tward J (2022). Nomograms for Metastasis-Free and Overall Survival for Pathologically Node Positive Prostate Cancer Patients Treated With or Without Radiation Therapy Plus Short-Term ADT. Clinical genitourinary cancer, 20, e263-e269.
- Peoples AR, Oswald LB, Ose J, Daniels B, Himbert C, Hathaway CA, Gigic B, Kirchhoff AC, Lin T, Grossman D, Tward J, Varghese TK Jr, Figueiredo JC, Toriola AT, Beck A, Scaife C, Shibata D, LaStayo P, Gonzalez B, Salas K, Ashworth A, Matsen C, Christenson C, Ma DS, Colman H, Hunt JP, Jones KB, Lee CJ, Larson M, Onega T, Akerley WL, Li CI, Schneider M, Penedo FJ, Siegel EM, Tworoger SS, Ulrich C (2022). Impact of the COVID-19 pandemic on rural and urban cancer patients' experiences, health behaviors, and perceptions. The Journal of rural health, 38(4), 886-899.
- Himbert C, Hathaway CA, Daniels B, Salas K, Ashworth A, Gigic B, Lin T, Viskochil R, Kirchhoff AC, Grossman D, Ose J, Tward J, Scaife C, Figueiredo JC, Toriola AT, Beck A, Shibata D, Gonzalez BD, Matsen C, Christenson C, Ma DS, Colman H, Hunt JP, Jones KB, Lee CJ, Larson M, Onega T, Akerley WL, Li CI, Schneider M, Penedo FJ, Siegel EM, Tworoger SS, Ulrich CM, Peoples A (2022). Factors associated with changes in exercise behaviors during the COVID-19 pandemic. Cancer causes & control, 33(7), 939-950.
- Hutten R, Khouri A, Parsons M, Tward A, Wilson T, Peterson J, Morrell G, Dechet C, O'Neil B, Schmidt B, Kokeny K, Lloyd S, Cannon D, Tward J, Sanchez A, Johnson (2022). The Clinical Significance of Maximum Tumor Diameter on MRI in Men Undergoing Radical Prostatectomy or Definitive Radiotherapy for Locoregional Prostate Cancer. Clinical genitourinary cancer, 20(6), e453-e459.
- Rock CB, Chipman JJ, Parsons MW, Weil CR, Hutten RJ, Tao R, Tward JD, Shah HR, Hu B, Stephens DM, Gaffney D (2022). Second Primary Malignancies in Diffuse Large B-cell Lymphoma Survivors with 40 Years of Follow Up: Influence of Chemotherapy and Radiation Therapy. Advances in radiation oncology, 7(6), 101035.
- Schaeffer EM, Srinivas S, Adra N, An Y, Barocas D, Bitting R, Bryce A, Chapin B, Cheng HH, D'Amico AV, Desai N, Dorff T, Eastham JA, Farrington TA, Gao X, Gupta S, Guzzo T, Ippolito JE, Kuettel MR, Lang JM, Lotan T, McKay RR, Morgan T, Netto G, Pow-Sang JM, Reiter R, Roach M, Robin T, Rosenfeld S, Shabsigh A, Spratt D, Teply BA, Tward J, Valicenti R, Wong JK, Berardi RA, Shead DA, Freedman-Cass D (2022). NCCN Guidelines® Insights: Prostate Cancer, Version 1.2023. Journal of the National Comprehensive Cancer Network, 20(12), 1288-1298.
- Flaig TW, Spiess PE, Abern M, Agarwal N, Bangs R, Boorjian SA, Buyyounouski MK, Chan K, Chang S, Friedlander T, Greenberg RE, Guru KA, Herr HW, Hoffman-Censits J, Kishan A, Kundu S, Lele SM, Mamtani R, Margulis V, Mian OY, Michalski J, Montgomery JS, Nandagopal L, Pagliaro LC, Parikh M, Patterson A, Plimack ER, Pohar KS, Preston MA, Richards K, Sexton WJ, Siefker-Radtke AO, Tollefson M, Tward J, Wright JL, Dwyer MA, Cassara CJ, Gurski L (2022). NCCN Guidelines® Insights: Bladder Cancer, Version 2.2022. Journal of the National Comprehensive Cancer Network, 20(8), 866-878.
- Jairath NK, Dal Pra A, Vince R Jr, Dess RT, Jackson WC, Tosoian JJ, McBride SM, Zhao SG, Berlin A, Mahal BA, Kishan AU, Den RB, Freedland SJ, Salami SS, Kaffenberger SD, Pollack A, Tran P, Mehra R, Morgan TM, Weiner AB, Mohamad O, Carroll PR, Cooperberg MR, Karnes RJ, Nguyen PL, Michalski JM, Tward JD, Feng FY, Schaeffer EM, Spratt D (2021). A Systematic Review of the Evidence for the Decipher Genomic Classifier in Prostate Cancer. European urology, 79(3), 374-383.
- Philipson RG, Romero T, Wong JK, Stish BJ, Dess RT, Spratt DE, Pilar A, Reddy C, Wedde TB, Lilleby WA, Fiano R, Merrick GS, Stock RG, Demanes DJ, Moran BJ, Braccioforte M, Tran PT, Martin S, Martinez-Monge R, Krauss DJ, Abu-Isa EI, Valle L, Chong N, Pisansky TM, Choo CR, Song DY, Greco S, Deville C, McNutt T, DeWeese TL, Ross AE, Ciezki JP, Tilki D, Karnes RJ, Klein EA, Tosoian JJ, Boutros PC, Nickols NG, Bhat P, Shabsovich D, Juarez JE, Kupelian PA, Rettig MB, Berlin A, Tward JD, Davis BJ, Reiter RE, Steinberg ML, Elashoff D, Horwitz EM, Tendulkar RD, Kishan A (2021). Patterns of Clinical Progression in Radiorecurrent High-risk Prostate Cancer. European urology, 80(2), 142-146.
- Tward J, Lenz L, Flake DD II,, Rajamani S, Olsson C, Kapoor DA, Mantz C, Liauw SL, Antic T, Shore N, Albertson D, Henderson J, Lee SP, Gay HA, Michalski J, Hung A, Raben D, Garraway I, Lewis MS, Nguyen PL, Marshall DT, Brawer MK, Stone S, Cohen (2021). The Clinical Cell-Cycle Risk (CCR) score Is Associated With Metastasis After Radiation Therapy and Provides Guidance on When to Forgo Combined Androgen Deprivation Therapy With Dose-Escalated Radiation. International journal of radiation oncology, biology, physics, 113(1), 66-76.
- Johnson SB, Parsons M, Dorff T, Moran MS, Ward JH, Cohen SA, Akerley W, Bauman J, Hubbard J, Spratt DE, Bylund CL, Swire-Thompson B, Onega T, Scherer LD, Tward J, Fagerlin (2021). Cancer Misinformation and Harmful Information on Facebook and Other Social Media: A Brief Report. Journal of the National Cancer Institute, 114(7), 1036-1039.
- Ravi P, Pond GR, Diamantopoulos LN, Su C, Alva A, Jain RK, Skelton WP 4th, Gupta S, Tward JD, Olson KM, Singh P, Grunewald CM, Niegisch G, Lee JL, Gallina A, Bandini M, Necchi A, Mossanen M, McGregor BA, Curran C, Grivas P, Sonpavde G (2021). Optimal pathological response after neoadjuvant chemotherapy for muscle-invasive bladder cancer: results from a global, multicentre collaboration. BJU international, 128(5), 607-614.
- Schaeffer E, Srinivas S, Antonarakis ES, Armstrong AJ, Bekelman JE, Cheng H, D'Amico AV, Davis BJ, Desai N, Dorff T, Eastham JA, Farrington TA, Gao X, Horwitz EM, Ippolito JE, Kuettel MR, Lang JM, McKay R, McKenney J, Netto G, Penson DF, Pow-Sang JM, Reiter R, Richey S, Roach Iii M, Rosenfeld S, Shabsigh A, Spratt DE, Teply BA, Tward J, Shead DA, Freedman-Cass D (2021). NCCN Guidelines Insights: Prostate Cancer, Version 1.2021. Journal of the National Comprehensive Cancer Network, 19(2), 134-143.
- Tward JD, Schlomm T, Bardot S, Canter DJ, Scroggins T, Freedland SJ, Lenz L, Flake DD 2nd, Cohen T, Brawer MK, Stone S, Bishoff (2021). Personalizing Localized Prostate Cancer: Validation of a Combined Clinical Cell-cycle Risk (CCR) Score Threshold for Prognosticating Benefit From Multimodality Therapy. Clinical genitourinary cancer, 19(4), 296-304.e3.
- Thomas JJ, Tward J (2021). Stage Presentation, Care Patterns, Treatment Outcomes, and Impact of Radiotherapy on Overall Survival for Adrenocortical Carcinoma. Clinical genitourinary cancer, 19(5), 417-424.
- Tward AE, Tward J (2021). The Stage at Presentation and Oncologic Outcomes for Agent Orange Exposed and Non-Exposed United States Veterans Diagnosed With Prostate Cancer. Clinical genitourinary cancer, 19(4), 369-369.e7.
- Hutten RJ, Parsons MW, Weil CR, Tward JD, Lloyd S, Sanchez A, Lester-Coll N, Johnson S (2021). Temporal Trends and Predictors in Diagnosing Pathologic Node-Positive Prostate Cancer in Clinically Node-Negative Patients. Clinical genitourinary cancer, 19(6), e360-e366.
- Greenberg SE, Hunt TC, Ambrose JP, Lowrance WT, Dechet CB, O'Neil BB, Tward J (2021). Clinical Germline Testing Results of Men With Prostate Cancer: Patient-Level Factors and Implications of NCCN Guideline Expansion. JCO precision oncology, 5,
- Kishan AU, Karnes RJ, Romero T, Wong JK, Motterle G, Tosoian JJ, Trock BJ, Klein EA, Stish BJ, Dess RT, Spratt DE, Pilar A, Reddy C, Levin-Epstein R, Wedde TB, Lilleby WA, Fiano R, Merrick GS, Stock RG, Demanes DJ, Moran BJ, Braccioforte M, Huland H, Tran PT, Martin S, Martínez-Monge R, Krauss DJ, Abu-Isa EI, Alam R, Schwen Z, Chang AJ, Pisansky TM, Choo R, Song DY, Greco S, Deville C, McNutt T, DeWeese TL, Ross AE, Ciezki JP, Boutros PC, Nickols NG, Bhat P, Shabsovich D, Juarez JE, Chong N, Kupelian PA, D'Amico AV, Rettig MB, Berlin A, Tward JD, Davis BJ, Reiter RE, Steinberg ML, Elashoff D, Horwitz EM, Tendulkar RD, Tilki (2021). Comparison of Multimodal Therapies and Outcomes Among Patients With High-Risk Prostate Cancer With Adverse Clinicopathologic Features. JAMA network open, 4(7), e2115312.
- Hutten RJ, Weil CR, Tward JD, Lloyd S, Johnson S (2021). Patterns of Care and Treatment Outcomes in Locoregional Squamous Cell Carcinoma of the Prostate. European urology open science, 23, 30-33.
- Kraus RD, Weil CR, Wells S, Tward JD, Groundland JS, Jones KB, Cannon D (2021). Radiation Therapy in Conjunction With Surgical Stabilization of Impending or Pathologic Fractures Secondary to Metastasis: Is There a Difference Between Single and Multifraction Regimens?. Advances in radiation oncology, 7(2), 100795.
- Szegedi M, Boehm C, Paxton A, Rassiah-Szegedi P, Sarkar V, Zhao H, Su F, Kokeny KE, Lloyd S, Tward J, Salter B (2020). Comparison of transperineal ultrasound image guidance technique to transabdominal technique for prostate radiation therapy. Medical physics, 47(12), 6113-6121.
- Canter DJ, Freedland S, Rajamani S, Latsis M, Variano M, Halat S, Tward J, Cohen T, Stone S, Schlomm T, Bishoff J, Bardot (2020). Analysis of the prognostic utility of the cell cycle progression (CCP) score generated from needle biopsy in men treated with definitive therapy. Prostate cancer and prostatic diseases, 23(1), 102-107.
- Flaig TW, Spiess PE, Agarwal N, Bangs R, Boorjian SA, Buyyounouski MK, Chang S, Downs TM, Efstathiou JA, Friedlander T, Greenberg RE, Guru KA, Guzzo T, Herr HW, Hoffman-Censits J, Hoimes C, Inman BA, Jimbo M, Kader AK, Lele SM, Michalski J, Montgomery JS, Nandagopal L, Pagliaro LC, Pal SK, Patterson A, Plimack ER, Pohar KS, Preston MA, Sexton WJ, Siefker-Radtke AO, Tward J, Wright JL, Gurski LA, Johnson-Chilla (2020). Bladder Cancer, Version 3.2020, NCCN Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network, 18(3), 329-354.
- Tward JD, O'Neil B, Boucher K, Kokeny K, Lowrance WT, Lloyd S, Cannon D, Stephenson RA, Agarwal N, Farr T, Petragallo R, Sherar NZ, Kunz I, Hofer A, Courdy S, Shrieve DC, Dechet (2020). Metastasis, Mortality, and Quality of Life for Men With NCCN High and Very High Risk Localized Prostate Cancer After Surgical and/or Combined Modality Radiotherapy. Clinical genitourinary cancer, 18(4), 274-283.e5.
- McComas K, Agarwal N, Bowen G, Maughan BL, Tward J (2020). Definitive Chemoradiotherapy for Locally Advanced, Lymph-node Positive, Nonmetastatic Penile Squamous Cell Carcinoma. In Press. Available online at DOI: https://doi.org/10.1016/j.clgc.2020.02.007. Clinical genitourinary cancer,
- Solanki AA, Savir-Baruch B, Liauw SL, Michalski J, Tward JD, Vapiwala N, Teoh EJ, LOCATE study group (2020). 18F-Fluciclovine Positron Emission Tomography in Men With Biochemical Recurrence of Prostate Cancer After Radical Prostatectomy and Planning to Undergo Salvage Radiation Therapy: Results from LOCATE. Practical radiation oncology, 10(5), 354-362.
- Usera BM, Creveling P, Tward J (2020). Impact and Outcomes of Pretreatment Total Serum Testosterone on Localized Prostate Cancer Patients. Prostate cancer, 2020, 8357452.
- Zhao H, Sarkar V, Wang B, Rassiah-Szegedi P, Szegedi M, Jessica Huang Y, Huang L, Tward J, Salter (2019). Calculation of delivered composite dose from Calypso tracking data for prostate cancer: And subsequent evaluation of reasonable treatment interruption tolerance limits. Journal of applied clinical medical physics, 20(8), 105-113.
- Greenberg S, Tward J, O'Neil (2019). Germline Variants in Highly Selected Patients With Prostate Cancer. JAMA oncology, 5(9), 1368-1369.
- Frandsen J, Orton A, Jensen R, Colman H, Cohen AL, Tward J, Shrieve DC, Suneja (2018). Patterns of care and outcomes in gliosarcoma: an analysis of the National Cancer Database. Journal of neurosurgery, 128(4), 1133-1138.
- Lin DW, Crawford ED, Keane T, Evans B, Reid J, Rajamani S, Brown K, Gutin A, Tward J, Scardino P, Brawer M, Stone S, Cuzick (2018). Identification of men with low-risk biopsy-confirmed prostate cancer as candidates for active surveillance. Urologic oncology, 36(6), 310.e7-310.e13.
- Tward (2018). The case for nonsurgical therapy of nonmetastatic penile cancer. Nature reviews. Urology, 15(9), 574-584.
- Sarkar V, Lloyd S, Paxton A, Huang L, Su FC, Tao R, Tward J, Zhao H, Salter (2018). Daily breathing inconsistency in pancreas SBRT: a 4DCT study. Journal of gastrointestinal oncology, 9(6), 989-995.
- Tward JD, Poppe MM, Hitchcock YJ, O'Neil B, Albertson DJ, Shrieve D (2018). Demographics, stage distribution, and relative roles of surgery and radiotherapy on survival of persons with primary prostate sarcomas. Cancer medicine, 7(12), 6030-6039.
- Burt LM, Shrieve DC, Tward J (2018). Factors influencing prostate cancer patterns of care: An analysis of treatment variation using the SEER database. Advances in radiation oncology, 3(2), 170-180.
- Bassett MR, Santiago-Lastra Y, Stoffel JT, Goldfarb R, Elliott SP, Pate SC, Broghammer JA, Gaither T, Breyer BN, Vanni AJ, Voelzke BB, Erickson BA, McClung CD, Presson AP, Tward JD, Myers JB, Neurogenic Bladder Research Group., Trauma and Urologic Reconstructive Network of Surgeons (2017). Urinary Diversion for Severe Urinary Adverse Events of Prostate Radiation: Results from a Multi-Institutional Study. The Journal of urology, 197(3 Pt 1), 744-750.
- Du K, Zhang C, Presson AP, Tward JD, Brant WO, Dechet C (2017). Orgasmic Function after Radical Prostatectomy. The Journal of urology, 198(2), 407-413.
- Mayer EN, Tward JD, Bassett M, Lenherr SM, Hotaling JM, Brant WO, Lowrance WT, Myers J (2017). Management of Radiation Therapy Oncology Group grade 4 urinary adverse events after radiotherapy for prostate cancer. BJU international, 119(5), 700-708.
- Spiess PE, Agarwal N, Bangs R, Boorjian SA, Buyyounouski MK, Clark PE, Downs TM, Efstathiou JA, Flaig TW, Friedlander T, Greenberg RE, Guru KA, Hahn N, Herr HW, Hoimes C, Inman BA, Jimbo M, Kader AK, Lele SM, Meeks JJ, Michalski J, Montgomery JS, Pagliaro LC, Pal SK, Patterson A, Plimack ER, Pohar KS, Porter MP, Preston MA, Sexton WJ, Siefker-Radtke AO, Sonpavde G, Tward J, Wile G, Dwyer MA, Gurski L (2017). Bladder Cancer, Version 5.2017, NCCN Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network, 15(10), 1240-1267.
- Salter BJ, Szegedi M, Boehm C, Sarkar V, Rassiah-Szegedi P, Wang B, Zhao H, Huang J, Huang L, Kokeny K, Tward J (2017). Comparison of 2 transabdominal ultrasound image guidance techniques for prostate and prostatic fossa radiation therapy. Practical radiation oncology, 7(2), e99-e107.
- Lindsay M. Burt, Matthew Poppe, Kristine E. Kokeny, David K. Gaffney, Dennis C. Shrieve, Jonathan D Twar (2017). Comparison of Treatment Modalities for Breast Cancer Arising In Hodgkin's Lymphoma Survivors. Journal of radiation oncology, 6(1), 65-72.
- Frandsen J, Orton A, Shrieve D, Tward (2017). Risk of Death from Prostate Cancer with and without Definitive Local Therapy when Gleason Pattern 5 is Present: A Surveillance, Epidemiology, and End Results Analysis. Cureus, 9(7), e1453.
- Gonzalez VJ, Hullett CR, Burt L, Rassiah-Szegedi P, Sarkar V, Tward JD, Hazard LJ, Huang YJ, Salter BJ, Gaffney D (2017). Impact of prone versus supine positioning on small bowel dose with pelvic intensity modulated radiation therapy. Advances in radiation oncology, 2(2), 235-243.
- Tward JD, Jarosek S, Chu H, Thorpe C, Shrieve DC, Elliott (2016). Time Course and Accumulated Risk of Severe Urinary Adverse Events After High- Versus Low-Dose-Rate Prostate Brachytherapy With or Without External Beam Radiation Therapy. International journal of radiation oncology, biology, physics, 95(5), 1443-1453.
- Merriman J, Tward J, Albertson D, Dechet C, Agarwal (2016). Durable Response to Treatment With Combination Radiotherapy and High-dose Interleukin-2 in Metastatic Chromophobe Variant Renal Cell Carcinoma. Journal of immunotherapy (Hagerstown, Md., 39(2), 101-3.
- Mohler JL, Armstrong AJ, Bahnson RR, D'Amico AV, Davis BJ, Eastham JA, Enke CA, Farrington TA, Higano CS, Horwitz EM, Hurwitz M, Kane CJ, Kawachi MH, Kuettel M, Lee RJ, Meeks JJ, Penson DF, Plimack ER, Pow-Sang JM, Raben D, Richey S, Roach M 3rd, Rosenfeld S, Schaeffer E, Skolarus TA, Small EJ, Sonpavde G, Srinivas S, Strope SA, Tward J, Shead DA, Freedman-Cass D (2016). Prostate Cancer, Version 1.2016. Journal of the National Comprehensive Cancer Network, 14(1), 19-30.
- Clark PE, Spiess PE, Agarwal N, Bangs R, Boorjian SA, Buyyounouski MK, Efstathiou JA, Flaig TW, Friedlander T, Greenberg RE, Guru KA, Hahn N, Herr HW, Hoimes C, Inman BA, Kader AK, Kibel AS, Kuzel TM, Lele SM, Meeks JJ, Michalski J, Montgomery JS, Pagliaro LC, Pal SK, Patterson A, Petrylak D, Plimack ER, Pohar KS, Porter MP, Sexton WJ, Siefker-Radtke AO, Sonpavde G, Tward J, Wile G, Dwyer MA, Smith (2016). NCCN Guidelines Insights: Bladder Cancer, Version 2.2016. Journal of the National Comprehensive Cancer Network, 14(10), 1213-1224.
- Ly D, Bagshaw HP, Anker CJ, Tward JD, Grossmann KF, Jensen RL, Shrieve D (2015). Local control after stereotactic radiosurgery for brain metastases in patients with melanoma with and without BRAF mutation and treatment. Journal of neurosurgery, 123(2), 395-401.
- Burt LM, Shrieve DC, Tward J (2014). Stage presentation, care patterns, and treatment outcomes for squamous cell carcinoma of the penis. International journal of radiation oncology, biology, physics, 88(1), 94-100.
- O'Neil BB, Presson A, Gannon J, Stephenson RA, Lowrance W, Dechet CB, Tward JD, Myers JB, Brant W (2014). Climacturia after definitive treatment of prostate cancer. The Journal of urology, 191(1), 159-63.
- Bagshaw HP, Pappas LM, Kepka DL, Tward JD, Gaffney D (2014). Patterns of care with brachytherapy for cervical cancer. International journal of gynecological cancer, 24(9), 1659-64.
- Mohler JL, Kantoff PW, Armstrong AJ, Bahnson RR, Cohen M, D'Amico AV, Eastham JA, Enke CA, Farrington TA, Higano CS, Horwitz EM, Kane CJ, Kawachi MH, Kuettel M, Kuzel TM, Lee RJ, Malcolm AW, Miller D, Plimack ER, Pow-Sang JM, Raben D, Richey S, Roach M 3rd, Rohren E, Rosenfeld S, Schaeffer E, Small EJ, Sonpavde G, Srinivas S, Stein C, Strope SA, Tward J, Shead DA, Ho M, National Comprehensive Cancer Network (2014). Prostate cancer, version 2.2014. Journal of the National Comprehensive Cancer Network, 12(5), 686-718.
- Aaron E. Wagner, Amol J. Ghia, Dennis C. Shrieve, Kristine E. Kokeny, William T. Lowrance, Jonathan D. Twar (2014). Adjuvant radiotherapy after prostatectomy: have randomized clinical trials had any impact?. Journal of radiation oncology, 3(4), 387-394.
- Ghia AJ, Tward JD, Anker CJ, Boucher KM, Jensen RL, Shrieve D (2014). Radiosurgery for melanoma brain metastases: the impact of hemorrhage on local control. Journal of radiosurgery and SBRT, 3(1), 43-50.
- Wagner AE, Chen A, Anker CJ, Tward JD, Ghia AJ, Jensen RL, Shrieve D (2014). Stereotactic radiosurgery for a single brain metastasis: factors impacting control. Journal of radiosurgery and SBRT, 3(2), 111-121.
- Jones G, Arthurs B, Kaya H, Macdonald K, Qin R, Fairbanks RK, Lamoreaux WT, Jawed I, Tward JD, Martincic D, Shivnani AT, Lee C (2013). Overall survival analysis of adjuvant radiation versus observation in stage I testicular seminoma: a surveillance, epidemiology, and end results (SEER) analysis. American journal of clinical oncology, 36(5), 500-4.
- Mohler JL, Kantoff PW, Armstrong AJ, Bahnson RR, Cohen M, D'Amico AV, Eastham JA, Enke CA, Farrington TA, Higano CS, Horwitz EM, Kawachi MH, Kuettel M, Lee RJ, Macvicar GR, Malcolm AW, Miller D, Plimack ER, Pow-Sang JM, Richey S, Roach M 3rd, Rohren E, Rosenfeld S, Small EJ, Srinivas S, Stein C, Strope SA, Tward J, Walsh PC, Shead DA, Ho M, National comprehensive cancer network (2013). Prostate cancer, version 1.2014. Journal of the National Comprehensive Cancer Network, 11(12), 1471-9.
- Tward JD, Kokeny KE, Shrieve D (2013). Radiation therapy for clinically node-positive prostate adenocarcinoma is correlated with improved overall and prostate cancer-specific survival. Practical radiation oncology, 3(3), 234-240.
- Jason J Schwartz, Heather F Thiesset, William R Hutson, Lisa Hazard, Jonathan Tward, James Carlisl (2013). Complete Resolution of a Malignant Biliary Stricture Using Combined Neoadjuvant Chemoradiation and Brachytherapy Boost Prior to Orthotopic Liver Transplantation. Journal of liver, 2(2),
- Cooke EW, Shrieve DC, Tward J (2012). Clinical versus pathologic staging for prostate adenocarcinoma: how do they correlate?. American journal of clinical oncology, 35(4), 364-8.
- Wang B, Tward JD, Salter B (2012). An evaluation of interference of inflatable penile prostheses with electromagnetic localization and tracking system. Medical physics, 39(8), 4807-11.
- Mohler JL, Armstrong AJ, Bahnson RR, Boston B, Busby JE, D'Amico AV, Eastham JA, Enke CA, Farrington T, Higano CS, Horwitz EM, Kantoff PW, Kawachi MH, Kuettel M, Lee RJ, MacVicar GR, Malcolm AW, Miller D, Plimack ER, Pow-Sang JM, Roach M 3rd, Rohren E, Rosenfeld S, Srinivas S, Strope SA, Tward J, Twardowski P, Walsh PC, Ho M, Shead D (2012). Prostate cancer, Version 3.2012: featured updates to the NCCN guidelines. Journal of the National Comprehensive Cancer Network, 10(9), 1081-7.
- Barney BM, Hitchcock YJ, Sharma P, Shrieve DC, Tward J (2011). Overall and cause-specific survival for patients undergoing lobectomy, near-total, or total thyroidectomy for differentiated thyroid cancer. Head & neck, 33(5), 645-9.
- Vern-Gross TZ, Shivnani AT, Chen K, Lee CM, Tward JD, MacDonald OK, Crane CH, Talamonti MS, Munoz LL, Small W J (2011). Survival outcomes in resected extrahepatic cholangiocarcinoma: effect of adjuvant radiotherapy in a surveillance, epidemiology, and end results analysis. International journal of radiation oncology, biology, physics, 81(1), 189-98.
- Erickson BA, Demanes DJ, Ibbott GS, Hayes JK, Hsu IC, Morris DE, Rabinovitch RA, Tward JD, Rosenthal S (2011). American Society for Radiation Oncology (ASTRO) and American College of Radiology (ACR) practice guideline for the performance of high-dose-rate brachytherapy. International journal of radiation oncology, biology, physics, 79(3), 641-9.
- Ghia AJ, Gonzalez VJ, Tward JD, Stroup AM, Pappas L, Gaffney D (2011). Primary vaginal cancer and chemoradiotherapy: a patterns-of-care analysis. International journal of gynecological cancer, 21(2), 378-84.
- Rassiah-Szegedi P, Wang B, Szegedi M, Tward J, Zhao H, Huang YJ, Sarkar V, Shrieve D, Salter (2011). Individualized margins for prostate patients using a wireless localization and tracking system. Journal of applied clinical medical physics, 12(3), 3516.
- O'Neil B. , Brant W.O. , Slack S.D., Tward J.D., Myers J.B (2011). Penile Cancer: Contemporary Considerations in Management of Local Disease. Current urology, 5(2), 62-71.
- Crosby MA, Tward JD, Szabo A, Lee CM, Gaffney D (2010). Does brachytherapy improve survival in addition to external beam radiation therapy in patients with high risk stage I and II endometrial carcinoma?. American journal of clinical oncology, 33(4), 364-9.
- Ghia AJ, Shrieve DC, Tward J (2010). Adjuvant radiotherapy use and patterns of care analysis for margin-positive prostate adenocarcinoma with extracapsular extension: postprostatectomy adjuvant radiotherapy: a SEER analysis. Urology, 76(5), 1169-74.
- Hitchcock YJ, Tward JD, Szabo A, Bentz BG, Shrieve D (2009). Relative contributions of radiation and cisplatin-based chemotherapy to sensorineural hearing loss in head-and-neck cancer patients. International journal of radiation oncology, biology, physics, 73(3), 779-88.
- Tward JD, Cachoeira CV, Salama ME, Lee RJ, Bowen G, Perkins SL, Glenn M, Confer M, Gaffney D (2009). Survival and recurrence in nonmycosis fungoides primary cutaneous lymphoma. Cancer journal (Sudbury, Mass.), 15(1), 87-92.
- Barney B, Tward JD, Skidmore T, Gaffney D (2009). Does radiotherapy or lymphadenectomy improve survival in endometrial stromal sarcoma?. International journal of gynecological cancer, 19(7), 1232-8.
- Chen J, Tward JD, Shrieve DC, Hitchcock Y (2008). Surgery and radiotherapy improves survival in patients with anaplastic thyroid carcinoma: analysis of the surveillance, epidemiology, and end results 1983-2002. American journal of clinical oncology, 31(5), 460-4.
- Skidmore TB, Lee CM, Abbott TM, Wiggins RH 3rd, Anderson GE, Tward JD, Hitchcock (2008). Gorham disease of the mandible: radiographic findings and radiotherapy response. Ear, nose, & throat journal, 87(6), E4-7.
- Brown AP, Chen J, Hitchcock YJ, Szabo A, Shrieve DC, Tward J (2008). The risk of second primary malignancies up to three decades after the treatment of differentiated thyroid cancer. The Journal of clinical endocrinology and metabolism, 93(2), 504-15.
- Hazard LJ, Tward JD, Shrieve D (2008). Adjuvant EBRT improves survival in patients with lymph-node-negative pancreatic cancer. Nature clinical practice. Oncology, 5(8), 438-9.
- Tward JD, Shrieve, D (2007). Brachytherapy Monotherapy for Older Men with Prostate Cancer. Journal of aging and health, 3(5), 653-661.
- Tward J, Glenn M, Pulsipher M, Barnette P, Gaffney (2007). Incidence, risk factors, and pathogenesis of second malignancies in patients with non-Hodgkin lymphoma. Leukemia & lymphoma, 48(8), 1482-95.
- Tward JD, Glenn M, Pulsipher M, Barnette P, Gaffney D (2007). Incidence, risk factors, and pathogenesis of second malignancies in patients with Non-Hodgkin lymphoma. Leukemia & lymphoma, 48(8), 1482-1495.
- Lee CM, Szabo A, Shrieve DC, Macdonald OK, Tward JD, Skidmore TB, Gaffney D (2007). Descriptive nomograms of adjuvant radiotherapy use and patterns of care analysis for stage I and II endometrial adenocarcinoma: A surveillance, epidemiology, and end results population study. Cancer, 110(9), 2092-100.
- Hazard L, Tward JD, Szabo A, Shrieve D (2007). Radiation therapy is associated with improved survival in patients with pancreatic adenocarcinoma: results of a study from the Surveillance, Epidemiology, and End Results (SEER) registry data. Cancer, 110(10), 2191-201.
- Hitchcock YJ, Bentz BG, Sharma PK, Fang C, Tward JD, Pappas L, Chen J, Hayes JK, Shrieve D (2007). Planned neck dissection after definitive radiotherapy or chemoradiation for base of tongue cancers. Otolaryngology--head and neck surgery, 137(3), 422-7.
- Macdonald OK, Lee RJ, Snow G, Lee CM, Tward JD, Middleton AW, Middleton GW, Sause W (2007). Prostate-specific antigen control with low-dose adjuvant radiotherapy for high-risk prostate cancer. Urology, 69(2), 295-9.
- Tward JD, Wendland MM, Shrieve DC, Szabo A, Gaffney D (2006). The risk of secondary malignancies over 30 years after the treatment of non-Hodgkin lymphoma. Cancer, 107(1), 108-15.
- Macdonald OK, Lee CM, Tward JD, Chappel CD, Gaffney D (2006). Malignant phyllodes tumor of the female breast: association of primary therapy with cause-specific survival from the Surveillance, Epidemiology, and End Results (SEER) program. Cancer, 107(9), 2127-33.
- Tward JD, Lee CM, Pappas LM, Szabo A, Gaffney DK, Shrieve D (2006). Survival of men with clinically localized prostate cancer treated with prostatectomy, brachytherapy, or no definitive treatment: impact of age at diagnosis. Cancer, 107(10), 2392-400.
- Furie BC, Ratcliffe JV, Tward J, Jorgensen MJ, Blaszkowsky LS, DiMichele D, Furie (1997). The gamma-carboxylation recognition site is sufficient to direct vitamin K-dependent carboxylation on an adjacent glutamate-rich region of thrombin in a propeptide-thrombin chimera. The Journal of biological chemistry, 272(45), 28258-62.
- Price MJ, Li LT, Tward JD, Bublik I, McBride WH, Lavey R (1995). Effect of nicotinamide and pentoxifylline on normal tissue and FSA tumor oxygenation. Acta oncologica (Stockholm, Sweden), 34(3), 391-5.
- Lavey RS, Taylor JM, Tward JD, Li LT, Nguyen AA, Chon Y, McBride W (1994). The extent, time course, and fraction size dependence of mouse spinal cord recovery from radiation injury. International journal of radiation oncology, biology, physics, 30(3), 609-17.
Review
- Zamboglou C, Doncker W, Christoforou AT, Arcangeli S, Berlin A, Blanchard P, Bauman G, Campi R, Castro E, Choudhury A, Pra AD, Draulans C, Desai N, Ferentinos K, Francolini G, Gillessen S, Grosu AL, Rivas JG, Hoelscher T, Hruby G, Jereczek-Fossa BA, Kamran S, Kasivisvanathan V, Kishan AU, Kounnis V, Loblaw A, Martin J, Mastroleo F, Merseburger AS, Miszczyk M, Mohamad O, Ost P, Papatsoris A, Peeken JC, Sanguedolce F, Sargos P, Schmidt-Hegemann N, Seibert TM, Shelan M, Siva S, Soeterik TFW, Spratt DE, Stenzl A, Strouthos I, Sutera P, Supiot S, Tilki D, Tran PT, Tree AC, Tward J, Ürün Y, Vapiwala N, Waddle MR, Wegener E, Zilli T, Murthy V, Thieme AH, Spohn (2025). oDigital pathology biomarkers for guiding radiotherapy-based treatment concepts in prostate cancer - a systematic review and expert consensus. Radiotherapy and oncology, 210, 111039.
- Tward J (2015). Editorial Review of: A Phase III Randomized Trial of MRI-Mapped, Dose-Escalated Salvage Radiotherapy Post-Prostatectomy: The MAPS Trial. 1(1),
Edited Book
- Gaffney DK, Shrieve DC, Anker CJ, Buyyounouski MK, Kong F, Hitchcock YJ, Tward J (2012). Radiation Oncology: Imaging and Treatment.
Book Chapter
- Jonathan D. Twar (2016). Prostate Cancer Bone Metastasis.
- Hilary P. Bagshaw, Jonathan D. Twar (2016). Current and Emerging Modalities.
- Jonathan D. Tward, Christopher J. Anker, David K. Gaffney and Glen M. Bowe (2012). Radiation Therapy and Skin Cancer.
- Ellen Cooke, Jonathan D. Tward, Dennis C. Shriev (2011). Anus and Rectum.
Editorial
- Spratt DE, Tward J (2020). Absolute versus Relative Benefit of Androgen Deprivation Therapy for Prostate Cancer: Moving Beyond the Hazard Ratio to Personalize Therapy. International journal of radiation oncology, biology, physics, 108(4), 899-902.
Letter
- Tward J, Lenz (2023). In Regard to Dess. International journal of radiation oncology, biology, physics, 115(1), 261-263.
- Shprecher DR, Grossmann KF, Tward J (2014). Sustained remission of Parkinson disease associated melanoma with immunotherapy. Parkinsonism & related disorders, 20(9), 1027-9.
Abstract
- Hunt T, Greenberg S, Ambrose J, O,Neil B, Tward J (2020). Factors associated with positive germline testing results in men with prostate cancer following NCCN guideline expansion. 38(suppl 6), abstr 230.
- Jonathan David Tward, Thorsten Schlomm, Stephen Bardot, Stephen J. Freedland, Lauren Lenz, Todd Cohen, Steven Stone, Jay Bishof (2020). Ability of the combined clinical cell-cycle risk score to identify patients that benefit from multi versus single modality therapy in NCCN intermediate and high-risk prostate cancer. 38(Suppl 6), abstr 346.
- Sumati Gupta, Benjamin Louis Maughan, Christopher B. Dechet, William Thomas Lowrance, Brock O Neil, Kristine E. Kokeny, Shane Lloyd, Jonathan David Tward, Kenneth M. Boucher, Neeraj Agarwa (2020). NEXT: A phase II, open-label study of nivolumab adjuvant to chemoradiation in patients (pts) with localized muscle invasive bladder cancer. 38(Suppl 6), Abstr tps605.
- Praful Ravi, Gregory Russell Pond, Leonidas Nikolaos Diamantopoulos, Rohit K. Jain, William Paul Skelton, Sumati Gupta, Jonathan David Tward, Kathleen Olson, Parminder Singh, Camilla Marisa Grunewald, Guenter Niegisch, Jae-Lyun Lee, Andrea Gallina, Marco Bandini, Andrea Necchi, Matthew Mossanen, Bradley Alexander McGregor, Catherine Curran, Petros Grivas, Guru Sonpavde (2020). Dissecting outcomes of patients (pts) with <ypT2N0 disease after neoadjuvant chemotherapy (NAC) for muscle invasive bladder cancer (MIBC): Results from a large, international, multicenter collaboration. 38(suppl), abstr 5043.
- Rebecca Levin-Epstein, Tahmineh Romero, Jessica Karen Wong, Kiri Cook, Robert Timothy Dess, Daniel Eidelberg Spratt, Brian Joseph Moran, Gregory Stephen Merrick, Phuoc T. Tran, David Jeffrey Demanes, Brad J. Stish, Daniel J. Krauss, Trude Baastad Wedde, Wolfgang Lilleby, Richard Stock, Jonathan David Tward, Michael L. Steinberg, Eric M. Horwitz, Rahul D. Tendulkar, Amar Upadhyaya Kisha (2020). Impact of initial treatment selection on clinical outcomes after biochemical failure in radiorecurrent high-risk prostate cancer. 38(Suppl 6), abstr 208.
- J.D. Tward, R. Petragallo, T. Farr, D.C. Shriev (2018). Comparative Effectiveness of Surgery versus Radiation Therapy for NCCN High and Very High Risk Prostate Cancer. 102(3), e147.
- Stone S, Cooperberg M, Flake, D, Davis JW, Moul JW, Tward, JD, Brawer M (2017). Evaluation of microarrays for measuring cell cycle progression (CCP) gene expression. Steven Stone, Matthew R. Cooperberg, Darl D Flake, John W. Davis, Judd W. Moul, Jonathan David Tward, Michael K. Brawer; Myriad Genetics, Inc., Salt Lake City, UT; University of California San Francisco Helen Diller Family Comprehensive Cancer Center, San Francisco, CA; The University of Texas MD Anderson Cancer Center, Houston, TX; Duke Cancer Institute, Duke University Medical Center, Durham, NC; University of Utah Huntsman Cancer Hospital, Salt Lake City, UT; Myriad Genetic Laboratories, Inc., Salt Lake City, UT. J Clin Oncol 35, 2017 (suppl; abstr e16566). 35(15_suppl), e16566-e16566.
- Frandsen J, Orton A, Shrieve DC, Tward (2016). Risk of Death from Prostate Cancer with and without Definitive Local Therapy When Primary or Secondary Gleason Pattern 5 Is Present: A Seer Analysis. Brachytherapy, 15, s202-203.
- Mitchell Bassett, Darshan Patel, Benjamin Breyer, Jonathan D Tward, Cameron Thorpe, Thomas Gaither, James Hotaling, William Brant, Jeremy Myer (2016). URINARY DIVERSION FOR COMPLICATIONS OF PROSTATE CANCER RADIATION TREATMENT. 193(4), 251.
- Kefu Du, Chong Zhang, Angela Presson, Jonathan Tward, William Brant, Christopher Deche (2016). Kefu Du, Chong Zhang, Angela Presson, Jonathan Tward, William Brant, Christopher Dechet. 195(4), e1043.
- Shore ND, Crawford ED, Cooperberg MR, Tward JD, Kaldate RR, Stone S, Brawer M (2016). Reduction in therapeutic burden from use of CCP test in treatment decisions among newly diagnosed prostate cancer patients independent of Charlson Comorbidity Index. 34(15_suppl), e16572-e16572.
- Jonathan D Tward, Lindsay M Burt, Dennis C Shriev (2015). Definitive treatment of localized prostate cancer: Time and geographic trends. presented at the Genitourinary Cancers Symposium. Journal of clinical oncology, 33,
- E. David Crawford, Neal Shore, Peter T. Scardino, John W. Davis, Jonathan D. Tward, Lowndes Harrison, Brent Evans, Lisa Fitzgerald, Steven Stone, Michael K. Brawe (2015). Performance of CCP assay in an updated series of biopsy samples obtained from commercial testing. presented at: Genitourinary Cancers Symposium. Journal of clinical oncology, 33,
- Cameron S. Thorpe, Jeremy B. Myers, Dennis C. Shrieve, Jonathan D. Twar (2015). Grade 3 or higher morbidity requiring urologic surgical management following curative-intent radiotherapy of localized prostate cancer: Patient characteristics. presented at: Genitourinary Cancers Symposium. Journal of clinical oncology, 33,
- Lindsay M.Burt, Dennis C. Shrieve, Jonathan D. Twar (2015). Prostate patterns of care. Journal of clinical oncology, 33,
- Yu-Huei Jessica Huang, Jonathan D Tward, Prema Rassiah, Hui Zhao, Vikren Sarkar, L Huang, Martin Szegedi, Kristine E. Kokeny, Bill J Salte (2015). Feasibility of MRI-Based Preplan On Low Dose Rate Prostate Brachytherapy. Medical physics, 42(6), 331906/.
- M. Szegedi, H. Zhao, P. Rassiah, V. Sarkar, J. Huang, L. Huang, JD Tward, K. Kokeny, B.J. Salte (2015). Clinical comparison of 2D transabdominal and 3D transperineal ultrasound image guidance methods for prostate RT. s494.
- ¿B.J. Salter, M. Szegedi, JD Tward, H. Zhao, V. Sarkar, P. Rassiah-Szegedi, L. Huang, J. Huan (2015). 3D transperineal ultrasound image guidance methods for prostate SBRT radiotherapy treatment. s460.
- Mitchell Bassett, Darshan Patel, Benjamin Breyer, Jonathan D Tward, Cameron Thorpe, Thomas Gaither, James Hotaling, William Brant, Jeremy Myer (2015). URINARY DIVERSION FOR COMPLICATIONS OF PROSTATE CANCER RADIATION TREATMENT. 193(4), e251.
- E. Crawford, N., Shore, P. Scardino, J. Davis, JD Tward, K. Moyes, L. Fitzgerald, S. STone, M. Brawe (2014). CCP Score Stratifies Risk for Prostate Cancer Patients at Biopsy: Initial Commercial Results. International journal of radiation oncology, biology, physics, 90(1), s433.
- E. Crawford, N. Shore, P. Scardino, J David, JD Tward, L Harrison, K Moyes, L Fitzgerald, S Stone, M. Brawe (2014). CCP score and risk stratification for prostate cancer patients at biopsy: Presented at the Genitourinary Cancers Symposium. Journal of clinical oncology, 32,
- vj gonzalez, c hullett, l Burt, P Rassiah, v Sarkar, JD Tward, LJ Hazard, JY Huang, BJ Salter, DK Gaffne (2013). Impact of Prone Versus Supine Positioning on Small Bowel Dose With Pelvic IMRT. International journal of radiation oncology, biology, physics, 87(2), s680.
- BJ Salter, Martin Szegedi, B Wang, JD Twar (2013). Presentation of a New Intrafractional Prostate Monitoring Method with Ultrasound Image Guidance During Radiotherapy Treatment. Medical physics, 40(6), 375.
- B Wanfg, V Sarkar, P Rassiah, H Zhao, YH Huang, M Szegedi, DC Shrieve, JD Tward, BJ Salte (2013). Direct Clinical Comparison of 2D Versus 3D Transabdominal Ultrasound Image Guidance Methods for Prostate Radiotherapy Treatment. Medical physics, 40(6), 375.
- S. Francis, CJ Anker, DG Adler, JD Tward, C Kristen, DC Shriev (2013). The Effect of Stents on Acute Toxicity in Esophageal Cancer. 87(2), s296.
- H Bagshaw, JD Tward, D Gaffne (2013). Patterns of Care With Brachytherapy for Cervical Cancer. 87(2), s410.
- AE Wagner, AJ Ghia, K Kokeny, DC Shrieve, JD Twar (2013). Adjuvant Radiation Therapy After Prostatectomy: Have Randomized Clinical Trials Had Any Impact?. 87(2), s174.
- LM Burt, A Wagner, DC Shrieve, JD Twar (2013). Comparison of Treatments for Breast Cancer Arising After Radiation Treatment for Hodgkin Lymphoma. 87(2), s247.
- D Ly, CJ Anker, JD Tward, DC Shriev (2013). Local Control After Stereotactic Radiosurgery (SRS) for Brain Metastases (BM) in Melanoma Patients With and Without BRAF Mutation and Treatment. 87(2), s282.
- B O'Neil, A Presson, J Gannon, RA Stephenson, W Lowrance, C Dechet, JD Tward, J Myers,WO Bran (2013). Climacturia after Definitive Treatment of Prostate Cancer. 19(1),
- C. Hullett, V.J. Gonzalez, L. Burt, P. Rassiah-Szegedi, V. Sarkar, J. Tward, L.J. Hazard, J. Huang, B.J. Salter, D.K. Gaffne (2012). Impact of BMI on Daily Setup Variation With Pelvic Radiation Therapy: Is Prone Positioning a Class Solution?. 84(3), s726.
- J.D. Tward, W.T. Lowrance, D.C. Shriev (2012). Demographics and Comparative Effectiveness of Surgery and Radiation Therapy in Men With Gleason Pattern 5 Prostate Cancer. 84(3), s386.
- D. Ly, D.C. Shrieve, J.D. Twar (2012). Demographics, Prognostic Factors, and Treatment Outcomes of Adrenocorticotrophic Carcinoma: A SEER Database Analysis From 1988-2008. 84(3), s424.
- B.E. Terakedis, M.E. Heilbrun, W.T. Lowrance, D.C. Shrieve, J.D. Twar (2012). The Effect of Prostate MRI on Cancer Staging and Radiation Therapy Treatment Recommendations. 84(3), S363-S364.
- J.D. Tward, D.C. Shriev (2011). Patterns of Care for Localized Prostate Cancer Stratified by Risk Group and Age at Diagnosis in the United States. 81(2), s102.
- M.M. Poppe, J.D. Tward, D.C. Shriev (2011). Trend of Declining Radiotherapy Use in Pediatric Low Grade Glioma. 81(2), s657.
- M Szegedi,P Rassiah-Szegedi, Y Huang, JD Tward, H Zhao, D Shrieve, and B Salte (2010). Post Implant Dosimetry for I 125 and Pd 103 Anchor and Non Anchor Seeds. Medical physics, 37(6), 3201.
- J.D. Tward, D.C. Shriev (2010). Radiotherapy is Correlated with Superior Survival in Clinically Node Positive Prostate Cancer. 78(3), s31.
- L. Burt, D.C. Shrieve, J.D. Twar (2010). Stage Presentation, Care Patterns, and Treatment Outcomes for Squamous Cell Carcinoma of the Penis. 78(3), s32-s33.
- P Rassiah-Szegedi, B Wang, JD Tward, M Szegedi, H Zhao, and B Salte (2009). Dosimetric Feasibility of Patient-Specific Margins for Prostate Patients Using a Wireless Localization and Tracking System. Medical physics, 36(6), 2497.
- B.J. Salter, B. Wang, J.D. Tward, D.C. Shriev (2009). Investigation of Potential Interference of 3 Piece Penile Prostheses with Electromagnetic Localization System. 75(3), S605-S606.
- E.W. Cooke, D.C. Shrieve, J.D. Twar (2009). Pathologic Staging Results in Substantially Higher Risk-stratification Compared with that Predicted by Clinical Risk-stratification in Men with Adenocarcinoma of the Prostate. 75(3), S297-S298.
- M.E. Montejo, B. Bentz, J. Hunt, J. Tward, D.C. Shrieve, Y.J. Hitchcoc (2009). IMRT with Simultaneous Integrated Boost (IMRT-SIB) Radiotherapy and Concurrent Cisplatin for Locoregional Advanced Squamous Cell Carcinoma of Head and Neck. 75(3), s416-s417.
- P. Rassiah, B. Wang, M. Szegedi, H. Zhao, Y. Huang, J.D. Tward, D.C. Shrieve, B.J. Salte (2009). Characterization of Potential Radiobiological Benefit from Design of Patient-specific Margins for Prostate Conformal Treatment using a Real Time Tracking System. 75(3), S586-S587.
- A.J. Ghia, D.C. Shrieve, J.D. Twar (2009). Adjuvant Radiotherapy Use and Patterns of Care Analysis for Margin Positive Prostate Adenocarcinoma with Extracapsular Extension. 75(3), S309.
- E.W. Cooke, D.C. Shrieve, J.D. Twar (2009). Pathologic Staging Results in Substantially Higher Risk-stratification Compared with that Predicted by Clinical Risk-stratification in Men with Adenocarcinoma of the Prostate. 75(3), S297-S298.
- Y Huang, B Wang, J Tward, D Shrieve, and B Salte (2009). A Comparison of Calypso Based Localization for Post Prostatectomy Patient in the Presence of High Geometric Residual (GR) Beacon Error: Comparison/correlation with Ultrasound Alignment. 36(6), 2480.
- Tward J.D., J.E. Sylvester, P.D. Grimm, D.C. Shriev (2008). The Risk of Second Primary Malignancies Following Brachytherapy Monotherapy, External Beam Plus Brachytherapy, or Radical Prostatectomy for Prostate Cancer. International journal of radiation oncology, biology, physics, 72(1 supp 1), S94.
- K. De Amorim Bernstein,Tward J.D., D.C. Shriev (2008). Patterns of Care for Prostate Cancer in the USA: Results from the SEER Database. International journal of radiation oncology, biology, physics, 72(1 Supp 1), S134.
- B.J. Salter, B. Wang, M. Szegedi, Tward J.D., D.C. Shriev (2008). Prostate Displacement during and after Transabdominal Ultrasound (US) Guidance, Monitored by a Real-time Tracking System. International journal of radiation oncology, biology, physics, 72(1 Supp 1), S146-S147.
- Salama M., Ho A., Tward JD., Gaffney DK, Perkins S (2008). BCL2 expression in primary cutaneous follicle center lymphoma: clinicopathologic study of 15 cases. 1(1),
- Tward JD, Stephenson R, Dechet C, Shrieve D (2008). Overall and cause-specific survival comparison in men undergoing prostatectomy versus external beam radiotherapy for prostate cancer with seminal vesicle invasion. 1(1),
- Tward JD, Cachoeira CV, Salama ME, Lee RJ, Bowen G, Perkins SL, Glenn M, Confer M, Gaffney D (2008). Survival and Recurrence in Non-Mycosis Fungoides Primary Cutaneous Lymphoma. 1(1),
- A.T. Shivnani, C.M. Lee,Tward J.D., O. Macdonald, L.L. Munoz, C. Crane, M.S. Talamonti, W. Smal (2007). Survival Outcomes for Adjuvant Radiation Therapy Versus no Radiation Therapy in Extrahepatic Cholangiocarcinoma: A Surveillance, Epidemiology, and End Results (SEER) Analysis. International journal of radiation oncology, biology, physics, 69(3, Supp 1), S283.
- N. Vudarla, I. Jawed, H. Kaya,Tward J.D., O. K. Macdonald, D. Martincic, D. K. Gaffney, A. T. Shivnani, T. L. Odom- Maryon, and C. M. Le (2007). Survival and secondary malignancy rates for adjuvant radiation therapy versus observation in stage I testicular seminoma: A Surveillance, Epidemiology, and End Results (SEER) analysis. Journal of clinical oncology, 25(18S),
- I. Jawed, C. M. Lee,Tward J.D., O. K. Macdonald, D. Martincic, N. Vudarla, R. K. Fairbanks, and H. Kay (2007). Survival outcomes for multiple myeloma over three decades: A Surveillance, Epidemiology, and End Results (SEER) analysis. Journal of clinical oncology, 25(18s),
- Tward JD, Hitchcock YJ, Sharma P, Shrieve D (2007). Overall and Cause-Specific Survival for Patients Undergoing Lobectomy, Near-Total, or Total Thyroidectomy for Differentiated Thyroid Cancer: Is there a Difference?. 1(1),
- Lee, C.M., MacDonald, K.,Tward JD, Shrieve, D.C., Szabo, A., Gaffney, D.K (2006). Patterns of care analysis of adjuvant therapy in the United States for stage I-II endometrial adenocarcinoma: A surveillance, epidemiology, and end results (SEER) population analysis. Gynecologic oncology, 101(1, Supp 1),
- C.M. Lee, A. Szabo, D.C. Shrieve, O.K. Macdonald,Tward J.D., D.K. Gaffne (2006). External Beam Radiation With or Without Vaginal Brachytherapy in Stage IC-II Endometrial Adenocarcinoma Provides a Survival Advantage: A Surveillance, Epidemiology, and End Results (SEER) Population Analysis. International journal of radiation oncology, biology, physics, 66(3 Supp 1), S39-S40.
- L.J. Hazard, Tward J.D., J. O’Connor, D. Shriev (2006). Pre and Post-Operative Radiation Therapy is Associated With Improved Survival in Patients With Pancreatic Adenocarcinoma: Results of a Study From the Surveillance, Epidemiology, and End Results (SEER) Registry Data. International journal of radiation oncology, biology, physics, 66(3, Supp 1), S81-83.
- O.K. Macdonald, C.M. Lee,Tward J.D., C.D. Chappell, D.K. Gaffne (2006). Malignant Phyllodes Tumor of the Female Breast: Determinants of Cause-Specific Survival From the Surveillance, Epidemiology, and End Results: (SEER) Program. International journal of radiation oncology, biology, physics, 66(3, Supp 1), S212.
- Tward J.D., A. Szabo, R. Orlandi, L. Dahlstrom, D.C. Shrieve, Y.J. Hitchcoc (2006). Relative Contributions of Radiation and Platinum-Based Chemotherapy to Sensorineural Hearing Loss in Head and Neck Cancer PatientsInternational Journal of Radiation Oncology*Biology*Physics, Volume 66, Issue 3, Supplement 1, 1 November 2006, Page S188. International journal of radiation oncology, biology, physics, 66(3, Supp 1), s188.
- Y.J. Hitchcock, K. Morton,Tward J.D., J.M. Hoffman, P. Sharma, B. Bentz, D.C. Shriev (2006). The Application of [18FDG] PET/CT in Treatment Planning and Response Evaluation for Patients Undergoing Radiotherapy for Head and Neck Cancer. International journal of radiation oncology, biology, physics, 66(3, Supp 1), S433-S434.
- A.P. Brown,Tward J.D., J. Chen, D.C. Shrieve, Y.J. Hitchcoc (2006). The Risk of Development and Factors Affecting the Pattern of Secondary Cancers Following Thyroid Cancer Diagnosis. International journal of radiation oncology, biology, physics, 66(3, Supp 1), S434.
- Tward JD, Shrieve, D.C (2006). The Risk of Development and Factors Affecting the Pattern of Secondary Cancers Following Diagnosis of Wilm’s Tumor. 1(1),
- Tward JD, Szabo, A., Gaffney, D.K., Shrieve, D. (2005). Does Age at Diagnosis Affect Outcome for Men Treated by Brachytherapy Versus Surgery for Clinically Localized Prostate Cancer?. Brachytherapy, 4(2), 79-120.
- Tward JD, Shrieve, D.C., Szabo, A., Gaffney, D. (2005). Does Radiotherapy Alter the Pattern of Secondary Malignancies after the Treatment of Non-Hodkin’s Lymphoma. 1(1), 1.
- Tward JD, Furie, B.C., Jacobs, M., Furie, (2000). A nine amino acid motif is sufficient to direct gamma carboxylation in-vitro. Blood, 96(11),
- Tward JD, Furie, B.C., Bouchard, B.A., Jacobs, M., Furie, B (1998). The vitamin K-dependent gamma glutamyl carboxylase recognition sequence: refinement of the model. 92(Supp),
- Tward JD, Furie, B.C., Bouchard, B.A., Jacobs, M., Furie, B (1997). Other amino acids than phenylalanine at position –16 in the carboxylation recognition site in the prothrombin propeptide can support gamma-carboxylation. 90(Supp),
- Lavey, R.S., Li, L.T., Bublick, I., Tward JD, McBride, W.H (1995). Elevation of hematocrit by recombinant human erythropoietin (r-HuEPO) improves tumor oxygenation. 1(1),
- Lavey, R.S., Tward JD, Li, L.T., Brooks, J., McBride, W.H., Dempsey, W.H., Dewhirst, M.W., Brizel, D.M (1994). Hematocrit is significantly associated with the oxygenation of murine Fsa tumors. International journal of radiation oncology, biology, physics, 31(Supplement),
- Price, M., Tward JD, Li, L.T., McBride, W.H., Lavey, R.S (1994). Effect of nicotinamide and pentoxyfylline on normal tissue and Fsa tumor oxygenation.
- Lavey, R.S., Tward JD, Li, L.T., McBride, W. (1994). Interactive effects of interleukin-2 and radiation on pulmonary metastases and normal tissue function.
Other
- Himbert C, Hathaway CA, Daniels B, Salas K, Ashworth A, Gigic B, Lin T, Viskochil R, Kirchhoff AC, Grossman D, Ose J, Tward J, Scaife C, Figueiredo JC, Toriola AT, Beck A, Shibata D, Gonzalez BD, Matsen C, Christenson C, Ma DS, Colman H, Hunt JP, Jones KB, Lee CJ, Larson M, Onega T, Akerley WL, Li CI, Schneider M, Penedo FJ, Siegel EM, Tworoger SS, Ulrich CM, Peoples A (2021). Impact of the COVID-19 pandemic on exercise habits among cancer patients. Research square,
- Xiang M, Ma TM, Savjani R, Pollom EL, Karnes RJ, Grogan T, Wong JK, Motterle G, Tosoian JJ, Trock BJ, Klein EA, Stish BJ, Dess RT, Spratt DE, Pilar A, Reddy C, Levin-Epstein R, Wedde TB, Lilleby WA, Fiano R, Merrick GS, Stock RG, Demanes DJ, Moran BJ, Huland H, Tran PT, Martin S, Martinez-Monge R, Krauss DJ, Abu-Isa EI, Alam R, Schwen Z, Pisansky TM, Choo CR, Song DY, Greco S, Deville C, McNutt T, DeWeese TL, Ross AE, Ciezki JP, Boutros PC, Nickols NG, Bhat P, Shabsovich D, Juarez JE, Chong N, Kupelian PA, Rettig MB, Zaorsky NG, Berlin A, Tward JD, Davis BJ, Reiter RE, Steinberg ML, Elashoff D, Horwitz EM, Tendulkar RD, Tilki D, Czernin J, Gafita A, Romero T, Calais J, Kishan A (2021). Performance of a Prostate-Specific Membrane Antigen Positron Emission Tomography/Computed Tomography-Derived Risk-Stratification Tool for High-risk and Very High-risk Prostate Cancer. JAMA network open, 4(12), e2138550.
Video/Film/CD/Web/Podcast
- Jonathan Twar (2015). Abbreviated Course ADT for Prostate Cancer.
- Jonathan Twar (2014). Is Death From Prostate Cancer the Right Clinical Endpoint to Guide Screening and Treatment Choices?.
Dr Tward goes above and beyond. Knowledgeable, compassionate and so caring. Such a positive experience. He has the best personality ever. God truly broke the mold when he made Dr Tward. We cannot thank him enough!
Doctor Tward is the most awesome doctor I've ever met in my life. Please keep saving lives. Love you man.
Not only is he the most knowledgeable medical person I have know but he is a very kind, patient, and treats you like he has personality know you all your life. As if you were his true friend.
Dr. Tward is highly engaging, listens and relates to his patients as he applies his vast experience to craft a bespoke treatment plan for his patients.
As good as it gets!
No one, in all aspects of what he does, could be better.
Best doctor ever! We have so much trust and faith in him and he has never ket us down! He has a wonderful and caring bedside manner and never makes us feel rushed he is very knowledable and extremely compassionate. As far as we are concerned he is a God send!
We only met on a virtual visit but we were very impressed and look forward to meeting him in person
Dr. Tward is a consummate professional. He exhibits the perfect balance of knowledge, understanding, listening and caring.
Amazing 'bedside' manner. Very empathetic, patient, caring and knowledgeable.
Dr. Tward is the consummate medical professional. Passionate about his patients outcomes. A thought leader in his area of expertise. And, an excellent communicator.
Very pleased with Dr Tward and the way he explained the different options of treatment available to me. Answered my questions before I could ask them. Left his office with confidence and relief after a long period of indecision.
First and foremost I credit Dr Tward with saving my life. His knowledge and precision about my cancer and skill with radiation was beyond perfect. My first Oncologist, who I admire and respect told me he did not have the tools nor skill to radiate where the cancer was located. Dr. Tward just smiled when we discussed that and told me he had the equipment and was a better shot! He is probably the most professional man I have ever met, and I know I am just one of hundreds of patients he sees yet he makes me feel like a personal friend. I am so blessed God brought him into my life.
DR. J0NATHAN D. TWARD, MD, DOES SUCH AN OUTSTANDING JOB OF PUTTING HIS PATIENTS AT EASE WHILE TAKING ALL THE TIME TO ANSWER ALL OF OUR QUESTIONS RELATIVE TO THE TREATMENT OPTIONS FOR MY PRESENT PROSTRATE CANCER ISSUES AT THIS TIME. DR. TWARD IS A DEFINITE CREDIT TO HIMSELF AND THE UNIVERSITY OF UTAH'S HUNTSMAN RADIOLOGY ONCOLGY DEPARTMENT. THE UNIVERSITY OF UTAH AND THE HUNTSMAN CANCER HOSPITAL RADIOLOGY AND ONCOLOGY DEPARTMENT ARE VERY LUCKY TO HAVE MEDICAL RADIOLOGY AND ONCOLOGY DOCTORS IN THEIR EMPLOY.. DR. TWARD IS DEFINITELY AN OUTSTANDING CREDIT TO HIMSELF AND TO THE HUNTSMAN CANCER HOSPITAL TO WHICH HE IS EMPLOYED.
I have a great degree of confidence in Dr. Tward. I have been his patient for over a decade; his expertise, advice, friendly manner and sincere concern for me, have been a an important support for me. It is greatly appreciated.
Dr. Tward is a kind and caring human beings filled with compassion for those under his care. His gentle manner is calming and healing. Dr. Tward tased the time in his busy schedule to engage you in your journey of healin. My encounter with cancer has been made easy with his, knowledge, wisdom and care. I am grateful to be his patience.
He is friendly, spent over an hour to answer questions, and explain therapy. His approach gave me confidence.
Awesome and truthful doctor. I'd trust him with my life! Wait a minute... I just did!
Outstanding in knowledge and caring.
Outstanding, was impressed 5 years ago when he took my case and still am!
Dr. Tward was outstanding. He answered all my questions clearly and straightforward. Talked in lay terms rather than medical jargon. Great bedside manner.
A wonderful man / doctor.
An extremely friendly and thoughtful and personal physician . His knowledge is evident, but he explains plans and treatments very clearly in layman's terminology.
Recreate is a hero He diagnoses my prostate cancer, quickly, painlessly and kindly. He found a quick, accurate and successful solution immediately and I have had lasting success without serious repercussions ever since. He s the best doctor I know Tommy Tanzer
I strongly recommend dr tward . I am in great care. I am very happy I have been able to get treated by him and his staff.
Dr. Tward tells it like it is in a good way. Very knowledgeable. Meeting him is a good experience.
Best Dr. I have ever met. Took the time to know me and my needs before we ever met. Most prepared Dr and staff. Do not hesitate to look for direction with your cancer here. I trust him with everything!
Dr. Tward is very kind and considerate in answering all your questions, and does so in away that you can understand what he is telling you
Dr Tward exceeded expectations on patient interaction. What I really appreciated was the willingness to answer questions without appearing rushed or behind on other appointments. Both my wife and I really liked Dr. Tward's straight-up candor and positive (without misleading optimism) discussion about prostate cancer and his enthusiasm for what he has learned through his experience. Other doctors I know with that kind of experience tend to become narcissistic and dogmatic with declining patient PR skills. My wife, who has had a hard time dealing with this diagnosis and continued cancer and he was able to connect with her in a way many doctors have not been able to. We really appreciated being able to be referred to him through Dr. Dechet.
Super guy with a very positive outlook. Took my concerns and fears and explained the risk in a very understandable way that was very warm and to the point. He took interest in me and was very prepared with my case and new what was going on without viewing his notes. Just very impressive!
Unfortunately he was running about 40 minutes late and got called away early as did some of his staff. Will try to talk to him by phone next week with my remaining questions. We drove up from St. George so it is difficult to reschedule.
I especially appreciated Dr. Tward's experience and breadth of knowledge about treating prostate cancer. His proposed treatment was gentler than I had expected.
Got t he care need
Dr. Tward is great! Very personable. He spent a lot of time with us, explaining EVERYTHING. He's very knowledgeable and experienced. His resident assistants were also great. I haven't had any treatments yet, but so far so good. If radiation treatment is of interest, I wouldn't hesitate to recommend him.
I immediately made a connection with Dr. Tward. Very nice, knowledgeable and knows what he's talking about. Very personable.
He's an oncological radiologist rock star!!!
I appreciate the candor and expertise when I interact with Dr. Tward. His explanations are easy to understand, allowing for a mutual agreement for subsequent courses of action and follow up.
Dr. Tward's ability to communicate is exceptional'even given that the most recent consultation occurred on the heels of a surgical intervention. He exudes professionalism and warmth, and quickly establishes a trusting relationship with patients and families. He has my highest recommendation.
As I said above, Dr. Tward was very helpful, went to length to explain things, took pains to see what kind of help I needed, clearly knew his stuff and was very friendly.
Doctor Tward is very confident with his understanding of the cancer.
One of the best doctors I have ever dealt with.
Dr. Tward is an ABSOLUTELY OUTSTANDING physician!!!
As I said previously " I immediately had a connection with Dr. Tward feeling calm and at ease with him as he told me his plan, as he said he would if talking with his Dad . Exactly as I would hope and expect him to do".
As stated previously, I came to Dr.Jonathan Tward for his professional openion and to ascertain a treatment plan for prostate cancer. Dr. Tward and his nurse Jane Anderson are amazing individuals. They.took the time to explain my cancer and discussed treatment plans and rendered their expert guidance and recomendations.Their friendly, personal and professional guidance was impeccable.
Dr.Tward is truly exceptional.His knowledge and experience comes to the fore quickly,which is very reassuring.He does his homework and is prepared to discuss your case,explain your diagnosis and lay out the options. He fully elicits your opinion and preferences re treatment options and follows through.
Dr Tward was very good at explaining the options that I had and benefits of the choices. I felt that I had options that I could live with.
Anyone blessed with the opportunity to have Dr. Tward as their doctor well receive the best possible care!!
Dr Tward is the kind of doctor I want on my team. He is the kind of doctor that makes you feel empowered in powerless situations. He left me feeling like I was in the driver seat, but he wouldn't hesitate to advise me with his best intentions even if it wasn't what I wanted to hear. Sometimes I feel doctors are trying to hard to handle me with kid gloves they won't give me actionable information I need to keep moving forward. Dr Tward did a great job of being candid and caring. Thank you very much
I'm grateful to have connected with Dr Tward and his team on my cancer journey. I know I am in good hands.
Dr Tward is the best doctor imaginable! Caring, conscientious and knowledgeable! Makes you feel you are his one and only concern! Simply the best!
Wonderful, caring and responsive physician!
I really like his positive confidence in his abilities, without being prideful. Straight forward ask and answered style.
Dr. Tward is absolutely the best. I have no doubt that he and his staff have saved my life.
Dr. Tward is amazing. Very affable as well as knowledgable.
Best doc anywhere!
Dr. Tward is an extremely bright physician who cares deeply about his patients. He always listens and provides answers to any questions.
I'm so glad Dr. Tward is my doctor and treating me
I really like this professionalism and his dedication and how he explained things where we understood what he was saying.
He's the man. Very thorough. I have confidence and trust in him.
Superb physician and easy to talk to and very knowledgeable and current in the treatments.
First impressions were ¿off the charts¿. He was caring, knowledgeable, and forthright. I trust him and believe he is ¿all in¿ to help me.
My first visit with Dr. Tward far exceeded my expectations. He was courteous, candid, and talked to me like a friend rather than a patient. Laid out several treatment options, pointed out the pros and cons of each, but let me decide which would be best for me and my family. I'm confident my treatment plan will be successful.
I tank my Lord he is my doctor
As noted previously, Dr. Tward was tremendously helpful, clear and compassionate. I feel he went "above and beyond" in his explanations to both me and my wife.
Excellent kind doctor
Over the top Thanks for all you do!
He listens carefully, explains thorougly and answers questions completely. He allows the patience thoughts feelings and background to be expressed and become part of the treatment plan. It is obvious he knows radiation well! He has a positive upbeat way about him!
Dr. Tward is excellent and very kind and caring
A real Pro. Very honest and forthright
There is no one better in his field
He is a very real compassionate person. You cant fake genuine concern and love. I consider him a close friend.
Dr. Tears is awesome.
I love Dr. Twards sense of humor:)
He's outstanding
Excellent and kind and very knowleadgable Doctor
The interaction I have had with Dr. Tward nave been very positive.
Dr. Tward was extremely professional, knowledgeable, fun to talk with and very precise in his observation of my condition. I felt very comfortable in making a decision to extend my care with his team.
Dr. Tward was willing and able to spend as much time with me as I needed. He's a rock star in the radiology oncology world.
Dr Tward is best in class... that is the highest compliment that I can pay him!!
Most amazing bedside manner anywhere and a very nice and genuine man.
He is the best-both as a doctor and as a person.
After discussing my health care with Dr. Tward, I am convinced he is the best choice .
Excellent
He was friendly, took the time necessary to communicate thoroughly about the situation and was highly reassuring.
Personable, extremely knowledgeable, caring, involves patients concerns and personal interests.
Very simple, he is the best on the planet!!
Excellent specialist.
Extremely knowledgeable not only in his specialty but also in related/associated medical areas. Uniquely personable and concerned for patient welfare. Extremely pleased with him as my doctor.
Dr. Tward is very committed to understanding my situation and plotting a course of action in full partnership with me. My wife and I are very pleased with every aspect of the appointment with him.
We have and do trust Dr Tward with our lives. And he s delivered.
Very thoughtful in his care and instills confidence in the treatment plan.
Treat options mine to decide
Excellent caring Doctor
Seems very professional and friendly.
Care and treatment have been excellent.
He has excellent people skills and expert in his specialty.
He is the best that there is... there is no higher praise then I can possibly give more then that?
He is very impressive as a doctor and as an Individual.
Very kind and understanding. Explain procedures clearly to me and listened carefully to my questions.
From our selections so far, it's obvious we have the highest regard for Dr. Tward
Great care and knowledge of my problem!
Dr Tward explained my options and gave me an opportunity to have all my questions answered in a way I could easily understand.
Stimulating conversation and a fun guy!
He informs very well but also listens to questions well.
Outstanding doctor conservative approach
Amazing Doctor. He put me at ease as soon as he walked into the exam room.
Very knowledgeable, kind and friendly guy.
He is great.
Dr. Tward was very patient and easily explained my situation in a manner I could understand.
Can't say enough good things about Dr. Tward. He is the kind of doctor you wish all doctors would emulate.
Excellent doctor and staff!
Very professional in sharing what my cancer is doing and the recommendation for treatment.
Excellent advice and info.
I have known Dr. Tward since 2011. He has always treated me with respect. He explains in terms a lay person can understand.
Dr. Tward is Amazing!!!!
Dr Tward is very personable. I appreciated his bedside manner. He was thorough in answering all my questions. He was not rushed and took time to illustrate and explain his diagnosis. In my first visit he inspired confidence in his competence and experience. I was referred to Dr. Tward by another University Cancer Center that was familiar with his expertise and I am very happy with the recommendation.
Explained in detail my prognosis and the plans to cure me Determined my understanding my situation answered all my questions very well With no pressure and left the choice to me
Exactly the kind of Doctor that everyone would want on their team!
Dr. Tward and his staff spent over 2hrs with me discussing my treatment needs which have become complicated and multi-faceted. He and his staff are very aware of all treatment options out there (including clinical trials) but when I touched on a subject that was within his knowledge but outside his specific area of expertise (e.g. RO) he deferred to "the MO" for consultation. Exactly what you want from a physician (e.g. "I may know of it and have a solid opinion on it but my colleagues who specialize in that aspect of the treatment are better qualified to guide you"). I feel I have a care team at HCI not just one doctor which is what I need going forward.
Dr. Tward is not only my caregiver but has become a friend who understands what I'm dealing with and devotes a great deal of his time to helping find solutions. He's fantastic.
Knowledgeable & caring. Very pleasant.
Dr. Tward is amazing! I am so glad that he will be taking care of me with my prostate cancer.
Again, Dr. Tward has very good bedside manner! He explained things in detail, made us feel we were cared for & took sufficient time with us.
He was able to detect my husbands tumors and kill them, even in the bones. My husbands cancer numbers are still dropping because of Dr. Tward. He really cares about us.
Caring complete and very trustworthy!
Dr. Tward checks off all the boxes for what I want in a provider. In his dealing with me, he has been personable, knowledgeable and explained plus-minus information regarding various treatment options. Highly recommended.
Dr Tward is very very good.
He explains test results and treatments exceedingly well. He cares!
Dr Tward is very very good.
Dr. Tward is amazing.
Looking forward to completing the planning process followed by requisite treatments.
Dr. Tward was very professional and put me at ease. I greatly appreciated that.
Dr. Tward was very professional and put me at ease. I greatly appreciated that.
Excellent
Dr. Tward and his staff was excellent.
Dr. Tward was exceptional! He provided excellent counsel and reviewed my situation with me. I answered all my questions. My wife and I feel very confident and the strategy we have in place now. Dr. Tward is an outstanding doctor. His resident Assistant was also very helpful.
Dr. Tward was excellent as usual. His intern was awful and condescending. His explaination about treatment was very poor.
Dr. Tward is a doctor I'm very comfortable to be around. He gave me all the time I needed.
Dr. Tward is the most caring physician I have ever been associated with.
Thanks to Dr. Tward, his staff and helpful colleagues, who have given me lots of help and hope over the years. Looking forward to continuing enjoying life . . .one-day-at-a-time . . . . And as the years pass . . .Thank you !
Excellent, data driven decision support
Very open. Refreshing to see him actually giving me the opportunity to get other opinions. Didn't happen when in California.
Tremendous feedback and advice
Excellent
It was a very good experience
Very informative with every question answered in detail. Did not feel rushed through the appointment
Excellent
Dr. Tward is an excellent care provider. The best.
Dr. Toward and resident, dr. Griffe, took a hour in their discussion. Helpful and direct
He was so compassionate about total care including impact on our lives that The patient was immediately comfortable and trusts the doctor to do what is best.
I have dealt with Dr Decket and Dr Tward. I think they are both great
The very best care I have ever recieved
Dr. Tward quickly gained my confidence and respect. I am very glad he is my Dr.!!!!
I firmly believe in seeking out the best Professionals for whatever questions or needs I might have especially when It comes to my health.
I have visited several doctors since my diagnosis but Dr Tward was the most outstanding. He provides a detailed explanation of the proposed treatment, the benefits and potential side effects. So we'll done I could decide on the spot to proceed. I never had any doctor who I felt such great trust and appreciation.
Very good.
Excellent consideration and answers for all my questions and concerns.
Best Doctor I have ever had
Dr. Tward answered all my questions, looked at all my history before he met with me. Very detailed in his discussions and I could not asked for anything more of a doctor. I trust him with my cancer issue.
I feel guilty for the amount of time Dr. Tward must take in brushing up on my notes, as It is no small feat or drain on his precious time. He not only is up to date on all recent events, his knowledge globally of past tests, evaluations, and remediation strategies always leaves me speechless. With Dr. Tward's grasp of the many aspects of my very complicated case, I can only imagine what tools, expertise, and wisdom he brings to bear to assist all of his other patients. Bravo Dr. Tward!
I am 4 years out from treatment. I was very fortunate to be treated at Huntsman and by doctor Tward
Dr Tward and his PA were well aware of my post-prostate surgery and radiation side-effects. As always, Dr. Tward was well of aware of my current issues, he listened to me, he interrupted my test results and gave me a path going forward.
Dr Tward is always very caring and through. He is terrific.
All of these are a 6.
Very informative
Both the intern and physician were excellent - very helpful and took the time to give me all of the information related to my case.
All staff were very good. Dr Tward was amazing. Explained everything very well. Very good Dr.
I was pleasantly surprised at how much time the Doctors were willing to spend with me to provide explanations and answer all is my questions.
Dr. Tward is very engaged in dealing with my issue and provides a full and complete review and discussion relating to my case. Lots of opportunity for questions and he responded with easy to understand responses.
I appreciate Dr Tward taking time to answer all of my questions and concerns.
Dr. Tward is the ultimate "fixer" when it comes to his profession, and the practice of medicine as a whole. He not only comes into a visit thoroughly prepared, having read everything available to him from my history. He postulates from free thinking, potential avenues for research, evaluation, and remediation in such an "out-of-the-box" way so as to never fail to impress the patient and make him wish that his other providers were just half as capable What a beautiful world it would be!
as stated this was a follow up after 4 yeas. my experience has been nothing but awesome
Thoughtful & extremely informative information, tremendous patience & great empathy.
Outstanding
See comments above. I need the entire process to move ahead at a quicker and more efficient speed.
Excellent communicator
the doctor gave me good explanation as far as he could with his little as he knows cuz I had biopsy surgery scheduled that afternoon and he didn't have that information doctor also wants a second MRI performed because he wants the huntsman center to perform the MRI hoping for better analysis and doctors are meeting this coming Wednesday a team of doctors to discuss my condition my prognosis My outcome and best possible treatment program so at this point doctor done everything he could but was limited on what he could do and not his fault
good
They really took a lot of time explaining things and answering questions. We were very impressed with everyone.
Not given enough information, and information that was not accurate by saying the shot I would get, would give me more time and a good life! That was totally wrog.
Dr Johnathan Tward is an excellent physician
Dr. Tward is by far the best doctor I have ever seen. He spent over 90 minutes with my wife and I, listening carefully, explaining things. For the first time in 3 years, I feel positive about my cancer.
listen to my concerns and provided appropriate feedback
Dr. Tward was exceptional, as was his staff
good.
Some items pertaining to the proposed treatment details were not discussed in the office, but showed up in the notes.
great and meaningful conversation
Great Dr.
very good advice
good
the bulk of the time was with an intern
Dr. Tward spent over an hour talking to me about therapeutic options and answered all the questions I had at the time. Excellent knowledge and care.
Dr. Tward was very willing to discuss my concerns and explain options
My Experience with Dr Tward was Exceptional
As always, Dr. Tward was very pleasant and provided very helpful information.
Dr. Tward explained all that is going on. He explained options and alternatives
Whether it be Dr. Tward, Jane RN, or Jessica the scribe, they could not have been more professional that they were. An outstanding crew.
all were caring and patient and professional
Dr Tward & "ALL STAFF" very friendly and informative. I was able to FaceTime my wife to be apart of my appointment, was fantastic!!!!!
very good
The Radiation crew at Huntsman saved my life
great
Dr. Tward is an excellent Dr.
Very good experience
very good
that was excellent like my Doctor is, giving me all the information, kindness, listening, and compassion than I never got with others hospitals
good
the hospital and staff are excellent
The quality of care and caring in Dr. Tward's clinic is the best experience I've had in health care.
My experience with Doctor Tward was most positive! He expressed genuine concern for my situation! I feel very grateful to have him for my physician!
Excellent
very good
Dr. Tward and his team are simply the best!
The appointment was a 2 1/2 year follow up on treatment for cancer
Dr Tward was a great guy to deal withI always feel like I have the best care in the world. I have recommended people to deal with your Drs
To put it as simply as I can, Dr. Tward sets the bar so high, I frankly don't know how he could improve.
Dr. Tward is extraordinary
Dr Tward and his staff do a an excellent job of giving me a real assessment of my health the status and options cancer is a terrible disease not just because it can kill you but what it takes beyond just life even a glimmer of hope means a great deal that is what happens at the Huntsman.